JAK1 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the DLD-1 human colorectal adenocarcinoma cell line, in which targeted disruption of the JAK1 gene creates a loss-of-function model for studying JAK-STAT signal transduction.
The DLD-1 cell line is an established epithelial model of colorectal adenocarcinoma, harboring well-characterized mutations in the APC tumor suppressor and KRAS oncogene. These genetic alterations drive constitutive activation of Wnt/??-catenin and MAPK signaling pathways, respectively, recapitulating key oncogenic events in colorectal cancer. As a widely used system in cancer biology, DLD-1 provides a relevant background for investigating how additional signaling perturbations influence tumor cell behavior and therapeutic responses.
JAK1 encodes a non-receptor tyrosine kinase that functions as a critical mediator of signaling from type I and type II cytokine receptors. Upon binding of cytokines like IL-6, IL-2, IL-4, IFN-??, or IFN-??, JAK1 is recruited to receptor complexes containing gp130, IFNGR1, or IFNAR1 and undergoes trans-phosphorylation with JAK2 or TYK2. Activated JAK1 then phosphorylates downstream STAT proteins, notably STAT1, STAT3, and STAT5, inducing their dimerization, nuclear translocation, and transcriptional regulation of target genes such as SOCS3, MYC, and BCL2. This JAK-STAT cascade controls processes including cell proliferation, apoptosis, and immune cell function, and is subject to negative regulation by SOCS family proteins.
In the context of DLD-1 cells with preexisting APC and KRAS mutations, disruption of JAK1 enables selective analysis of JAK-STAT pathway contributions independent of deregulated Wnt and MAPK activity. This model is particularly pertinent for investigating how loss of JAK1 alters cellular responses to inflammatory cytokines, STAT3-dependent transcriptional programs, and tumor survival mechanisms. Given the associations of JAK1 with colorectal cancer progression, inflammatory bowel disease, and immune checkpoint regulation, these knockout cells serve as a valuable platform for dissecting oncogenic and immune-modulatory signaling in a genetically defined colorectal background.
Researchers can utilize these polyclonal knockout cells in a range of functional assays to probe JAK1-dependent biology. Cytokine stimulation experiments coupled with western blotting for phospho-STAT3 or RT-qPCR for STAT target genes allow direct assessment of pathway activation. Proliferation and apoptosis assays reveal the consequences of JAK1 loss on cell growth and death under basal or cytokine-challenged conditions. Pharmacological inhibition studies using JAK1/2 inhibitors such as ruxolitinib enable comparisons between genetic and chemical blockade of the pathway. Additionally, transcriptomic analyses via RNA-seq can identify gene expression networks reliant on JAK1. Collectively, these applications support research in colorectal cancer biology, inflammatory signaling, and therapeutic targeting of JAK-STAT pathways in solid tumors. For additional technical information or ordering inquiries, please contact Ascent Research.
